Public Hearing to Address Insulin Prices, Biosimilar Insulins – Drug for nerve pain boosts high for opioid abusers.

7Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Public Hearing to Address Insulin Prices, Biosimilar Insulins – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

The FDA is hosting a public hearing to discuss access to affordable insulin products, and the regulatory issues related to the development and evaluation of biosimilar and interchangeable insulin products.1-2 The hearing will take place May 13, 2019 at the agency’s headquarters in Silver Spring, Maryland.1

According to the agency, access to insulin can be increasingly difficult for some individuals to obtain as list prices regularly increase by double digits. These increases have raised serious concerns about the ability for many patients in need of insulin for diabetes management and survival to access this medication. This week, a House of Representatives subcommittee heard from stakeholders affected by the rising costs of insulin, and with the hearing, the Agency intends to “inform steps the FDA can take to advance access to insulin products, including biosimilar and interchangeable insulin products,” said FDA Commissioner Scott Gottlieb, MD, in a prepared statement.2

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.